Clinical Trials on Nevi

Total 2711 results

Biocad

Completed

Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma

Melanoma

Russian Federation
Cliniques universitaires Saint-Luc- Université...
Immutep S.A.S.

Terminated

Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

Melanoma

Belgium
Saint John's Cancer Institute

Terminated

Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration

Melanoma

United States
Hoffmann-La Roche

Completed

A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU]) (MELANIS)

Melanoma

France
M.D. Anderson Cancer Center
Schering-Plough; Eisai Inc.

Terminated

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

Melanoma

United States
Providence Health & Services

Terminated

Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC)

Melanoma

United States
Adil Daud

Completed

A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma

Melanoma

United States
Ahmad Tarhini
Prometheus Laboratories

Terminated

A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study

Melanoma

United States
John Kirkwood
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma (12-107)

Melanoma

United States
Peking University Cancer Hospital & Institute

Unknown

HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma

Melanoma

China
Bristol-Myers Squibb

Completed

Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy

Melanoma

United States
Bristol-Myers Squibb

Completed

Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States

Melanoma

United States
University of Pittsburgh
Schering-Plough

Terminated

Pilot Study of IFN α2b for Melanoma Patients

Melanoma

United States
GlaxoSmithKline

Completed

Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma

Melanoma

Australia, United States
Merck Sharp & Dohme LLC

Completed

High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)

Melanoma
Radboud University Medical Center

Completed

Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients

Melanoma

Netherlands
Massachusetts General Hospital

Terminated

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

Melanoma

United States
Xijing Hospital

Unknown

18F-Labeled Picolinamide PET Imaging of Melanoma Diagnosis

Melanoma

China
Radboud University Medical Center

Completed

Natural Dendritic Cell Vaccines in Metastatic Melanoma Patients

Melanoma

Netherlands
Angimmune LLC
University of Louisville

Terminated

A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma

Melanoma

United States
Bristol-Myers Squibb
Medarex

Completed

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Melanoma

United States, Spain, Austria, Italy, Sweden, Russian Federation, Ukraine, Finland, Norway, Poland
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Terminated

Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma

Melanoma

United States
Bristol-Myers Squibb

Completed

A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

Melanoma

South Africa, United States, Spain, France, Italy, Belgium, Austria, Israel, Germany, Norway, Canada, Brazil, Poland, Denmark, Czech Republic, Russian Federation, Ukraine, Argentina
Centre Hospitalier Universitaire de Besancon

Unknown

Study of Anti-telomerase T CD4 Immunity in Melanoma (LyTéloMel)

Melanoma

France
Sidney Kimmel Comprehensive Cancer Center at Johns...
The John P. Hussman Foundation

Completed

Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma

Melanoma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma

Melanoma

United States
BioVex Limited
Covance

Completed

An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)

Melanoma
AVAX Technologies

Unknown

M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma

Melanoma
National Cancer Institute (NCI)

Terminated

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Melanoma

United States
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)

Melanoma
Bristol-Myers Squibb

Completed

Phase II, 2nd Line Melanoma - RAND Monotherapy

Melanoma

France, Italy, United States, Germany, Canada, Denmark
Astellas Pharma Inc

Completed

A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma

Melanoma

United States, Canada
Merck Sharp & Dohme LLC

Completed

Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)

Melanoma
Maimónides Biomedical Research Institute of Córdoba
Mount Sinai Hospital, New York

Unknown

Application of Genomic Techniques and Image Processing Using Artificial Intelligence to Obtain a Predictor Model Risk of Melanoma

Melanoma
Dr. Nina Bhardwaj
Cancer Research Institute, New York City

Completed

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

Melanoma

United States
Redwood Regional Medical Group

Completed

High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes

Melanoma

United States
Northwestern University

Completed

Melanoma Simulation Model With Smartphone Devices: Training Physicians for Early Detection of Melanoma

Melanoma

United States
Boehringer Ingelheim

Completed

Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma

Melanoma
Washington University School of Medicine

Withdrawn

Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma

Melanoma
Morphotek

Terminated

Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma

Melanoma

United States
Prisma Health-Upstate
Oncolix, Inc.

Terminated

Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma

Melanoma

United States
Bart Neyns

Completed

A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Melanoma

Belgium
University of Arizona

Completed

Cognitive Effects of Interferon in Patients With Melanoma

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma

Melanoma

United States
Cliniques universitaires Saint-Luc- Université...
Institut Pasteur

Unknown

Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients (THERAVAC)

Melanoma

Belgium
Rigshospitalet, Denmark

Unknown

The Value of Preoperative Dynamic Lymphscintigraphy and Ultrasoundscanning, Eventually With FNA, for Identification of Malignant Sentinel Node(s) in Patients With Melanoma

Melanoma

Denmark
AstraZeneca

Completed

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Melanoma

United States, Italy, Spain, Sweden, Belgium, Canada, Poland, Switzerland, France, Russian Federation, United Kingdom, Australia, Argentina, Germany, Netherlands, Israel, South Africa, Austria, Greece, Mexico, Slovakia
AstraZeneca

Completed

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

Melanoma

United States
AstraZeneca

Terminated

A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma

Melanoma

United States
Novartis Pharmaceuticals

Completed

EPO906 Therapy in Patients With Advanced Melanoma

Melanoma

United States

3

Subscribe